

Europe Medical Enzymes Market Forecast 2022-2030

Market Report | 2022-06-21 | 160 pages | Inkwood Research

AVAILABLE LICENSES:

- Single User Price \$1250.00
- Global Site License \$1500.00
- \$2000.00

Report description:

KEY FINDINGS

The Europe medical enzymes market is evaluated to grow with a CAGR of 5.86% during the forecasted period of 2022 to 2030. Key factors strengthening the regional market's growth are the increasing demand for enzymes in the pharmaceutical sector, the rise in research and development activities, and the growing need for nutraceuticals and dietary supplements following the COVID-19 pandemic.

MARKET INSIGHTS

The Europe medical enzymes market growth evaluation encompasses a detailed assessment of the United Kingdom, Poland, Belgium, Germany, France, Italy, and Rest of Europe. According to industry estimates, France spent more than 11% of its gross domestic product (GDP) on healthcare. Moreover, according to the Organisation for Economic Co-operation and Development (OECD), cancer was the leading cause of death in the country, accounting for 28.5% of all fatalities in 2014, followed by cardiovascular diseases. In this regard, the rise in alcohol and tobacco consumption is the major cause of diseases in France. As a result, the application of enzymes for treating various conditions and diseases is a key driver of the market's growth in the country.

On the other hand, Italy is one of the first countries to introduce advanced therapies into the European market. With the increase in research in advanced therapies as well as diagnosis, the Italian biotech industry is experiencing rapid expansion. Moreover, investments in research and vaccines have increased in the country, as well. Therefore, the aforementioned factors are expected to propel the Europe medical enzymes market growth over the forecasting years.

COMPETITIVE INSIGHTS

Eminent firms operating in the market include BBI Solutions, Sanofi, BASF, etc.

Our report offerings include:

- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Table of Contents:

TABLE OF CONTENTS

- 1. RESEARCH SCOPE & METHODOLOGY
- 1.1. STUDY OBJECTIVES
- 1.2. SCOPE OF STUDY
- 1.3. METHODOLOGY
- 1.4. ASSUMPTIONS & LIMITATIONS
- 2. EXECUTIVE SUMMARY
- 2.1. MARKET SIZE & ESTIMATES
- 2.2. MARKET OVERVIEW
- 3. MARKET DYNAMICS
- 3.1. KEY DRIVERS
- 3.1.1. INCREASED INVESTMENT IN HEALTHCARE RESEARCH AND FACILITIES
- 3.1.2. WIDENING APPLICATION IN MEDICAL INDUSTRY
- 3.1.3. GROWING PREVALENCE OF CHRONIC DISEASES AND RISING AGING POPULATION
- 3.2. KEY RESTRAINTS
- 3.2.1. HANDLING AND SAFETY OF ENZYMES
- 3.2.2. REGULATIONS FOR MEDICAL ENZYMES
- 4. KEY ANALYTICS
- 4.1. IMPACT OF COVID-19 ON MEDICAL ENZYMES MARKET
- 4.2. KEY MARKET TRENDS
- 4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
- 4.4. OPPORTUNITY MATRIX
- 4.5. VENDOR LANDSCAPE
- 4.6. VALUE CHAIN ANALYSIS
- 4.6.1. RESEARCH AND DEVELOPMENT
- 4.6.2. OPERATIONS
- 4.6.3. OUTBOUND LOGISTICS
- 4.7. KEY BUYING CRITERIA
- 4.7.1. COST
- 4.7.2. QUALITY
- 4.7.3. APPLICATION
- 4.8. REGULATORY FRAMEWORK
- 5. MARKET BY TYPE
- 5.1. HYDROLASE
- 5.1.1. HYALURONIDASE
- 5.1.2. LYSOZYMES

Scotts International. EU Vat number: PL 6772247784

- 5.1.3. OTHER HYDROLASES ENZYMES
- 5.2. THROMBOLYTIC
- 5.2.1. STREPTOKINASE
- 5.2.2. UROKINASE
- 5.2.3. OTHER THROMBOLYTIC ENZYMES
- 5.3. DIGESTIVE ENZYME
- 5.3.1. LACTASE
- 5.3.2. L-ASPARAGINASE
- 5.3.3. OTHER DIGESTIVE ENZYMES
- 5.4. ENDONUCLEASE
- 5.4.1. BENZONASE
- 5.4.2. OTHER ENDONUCLEASES
- 6. MARKET BY APPLICATION
- 6.1. DISEASE TREATMENT
- 6.2. DIAGNOSTIC TOOLS
- 6.3. BIOMEDICAL RESEARCH
- 6.4. OTHER APPLICATIONS
- 7. GEOGRAPHICAL ANALYSIS
- 7.1. EUROPE
- 7.1.1. MARKET SIZE & ESTIMATES
- 7.1.2. KEY GROWTH ENABLERS
- 7.1.3. KEY CHALLENGES
- 7.1.4. KEY PLAYERS
- 7.1.5. COUNTRY ANALYSIS
- 7.1.5.1. UNITED KINGDOM
- 7.1.5.2. GERMANY
- 7.1.5.3. FRANCE
- 7.1.5.4. ITALY
- 7.1.5.5. BELGIUM
- 7.1.5.6. POLAND
- 7.1.5.7. REST OF EUROPE
- 8. COMPETITIVE LANDSCAPE
- 8.1. KEY STRATEGIC DEVELOPMENTS
- 8.1.1. MERGERS & ACOUISITIONS
- 8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 8.1.3. PARTNERSHIPS & AGREEMENTS
- 8.1.4. BUSINESS EXPANSIONS & DIVESTITURES
- 8.2. COMPANY PROFILES
- 8.2.1. ADVANCED ENZYMES
- 8.2.2. AMANO ENZYME
- 8.2.3. BASF
- 8.2.4. BBI SOLUTIONS
- 8.2.5. BRAIN
- 8.2.6. CODEXIS
- 8.2.7. CPC BIOTECH
- 8.2.8. DSM
- 8.2.9. DUPONT

Scotts International. EU Vat number: PL 6772247784

8.2.10. NOVOZYMES

8.2.11. NOVUS

8.2.12. ROCHE

8.2.13. SANOFI

8.2.14. SEKISUI

8.2.15. THERMO FISHER SCIENTIFIC



☐ - Print this form

To place an Order with Scotts International:

Europe Medical Enzymes Market Forecast 2022-2030

Market Report | 2022-06-21 | 160 pages | Inkwood Research

☐ - Complete the re	elevant blank fields and sign			
Send as a scann	ned email to support@scotts-inte	rnational.com		
ORDER FORM:				
Select license	License		Price	
	Single User Price			\$1250.00
	Global Site License			\$1500.00
				\$2000.00
			VAT Total	
			Total	
Email*		Phone*		
First Name*		Last Name*		
Job title*				
Company Name* [EU Vat / Tax ID / NIP number*		IIP number*	
Address*		City*		
Zip Code*		Country*		
		Date	2025-05-07	
		Signature		

Scotts International. EU Vat number: PL 6772247784